The FDA highlighted cases where people overdosed on off-brand injections of semaglutide, dispensed from compounding pharmacies with inaccurate measurements, leading to overdose symptoms and hospitalizations.
Compounding pharmacies can legally produce personalized formulations of drugs under specific circumstances, but the imitations lack FDA approval and necessary safety standards, posing risks to patients in the absence of approved drugs.
[
Collection
]
[
|
...
]